vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and CS Disco, Inc. (LAW). Click either name above to swap in a different company.
CS Disco, Inc. is the larger business by last-quarter revenue ($41.9M vs $21.9M, roughly 1.9× Cue Biopharma, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -23.0%, a 30.2% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 14.3%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 7.9%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
CS Disco, Inc. is a leading legal technology provider that develops cloud-based software solutions for legal practitioners. Its core offerings include e-discovery, document review, case management, and legal workflow automation tools, serving law firms, corporate legal teams, and government legal departments primarily in North America.
CUE vs LAW — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $41.9M |
| Net Profit | $1.6M | $-9.6M |
| Gross Margin | — | 74.2% |
| Operating Margin | 9.0% | 1.7% |
| Net Margin | 7.2% | -23.0% |
| Revenue YoY | 1292.3% | 14.3% |
| Net Profit YoY | 116.7% | 15.6% |
| EPS (diluted) | $0.05 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $41.9M | ||
| Q4 25 | $21.9M | $41.2M | ||
| Q3 25 | $2.1M | $40.9M | ||
| Q2 25 | $3.0M | $38.1M | ||
| Q1 25 | $421.0K | $36.7M | ||
| Q4 24 | $1.6M | $37.0M | ||
| Q3 24 | $3.3M | $36.3M | ||
| Q2 24 | $2.7M | $36.0M |
| Q1 26 | — | $-9.6M | ||
| Q4 25 | $1.6M | $-8.5M | ||
| Q3 25 | $-7.4M | $-13.7M | ||
| Q2 25 | $-8.5M | $-10.8M | ||
| Q1 25 | $-12.3M | $-11.4M | ||
| Q4 24 | — | $-25.2M | ||
| Q3 24 | $-8.7M | $-9.2M | ||
| Q2 24 | $-10.2M | $-10.8M |
| Q1 26 | — | 74.2% | ||
| Q4 25 | — | 75.1% | ||
| Q3 25 | — | 75.5% | ||
| Q2 25 | — | 74.6% | ||
| Q1 25 | — | 74.1% | ||
| Q4 24 | — | 74.2% | ||
| Q3 24 | — | 73.1% | ||
| Q2 24 | — | 74.2% |
| Q1 26 | — | 1.7% | ||
| Q4 25 | 9.0% | -22.4% | ||
| Q3 25 | -353.4% | -35.3% | ||
| Q2 25 | -292.3% | -31.0% | ||
| Q1 25 | -2921.4% | -34.4% | ||
| Q4 24 | — | -70.6% | ||
| Q3 24 | -264.2% | -30.0% | ||
| Q2 24 | -390.6% | -34.4% |
| Q1 26 | — | -23.0% | ||
| Q4 25 | 7.2% | -20.7% | ||
| Q3 25 | -346.6% | -33.4% | ||
| Q2 25 | -287.1% | -28.4% | ||
| Q1 25 | -2911.4% | -31.1% | ||
| Q4 24 | — | -68.1% | ||
| Q3 24 | -259.6% | -25.3% | ||
| Q2 24 | -382.7% | -30.1% |
| Q1 26 | — | $-0.15 | ||
| Q4 25 | $0.05 | $-0.13 | ||
| Q3 25 | $-0.07 | $-0.22 | ||
| Q2 25 | $-0.09 | $-0.18 | ||
| Q1 25 | $-0.17 | $-0.19 | ||
| Q4 24 | — | $-0.43 | ||
| Q3 24 | $-0.17 | $-0.15 | ||
| Q2 24 | $-0.20 | $-0.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $103.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.4M | $123.9M |
| Total Assets | $42.2M | $162.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $103.0M | ||
| Q4 25 | $27.1M | $114.6M | ||
| Q3 25 | $11.7M | $113.5M | ||
| Q2 25 | $27.5M | $114.5M | ||
| Q1 25 | $13.1M | $118.8M | ||
| Q4 24 | $22.5M | $129.1M | ||
| Q3 24 | $32.4M | $126.8M | ||
| Q2 24 | $30.0M | $130.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — |
| Q1 26 | — | $123.9M | ||
| Q4 25 | $26.4M | $128.1M | ||
| Q3 25 | $13.2M | $130.6M | ||
| Q2 25 | $18.2M | $137.9M | ||
| Q1 25 | $6.6M | $142.2M | ||
| Q4 24 | $17.5M | $147.5M | ||
| Q3 24 | $25.4M | $167.3M | ||
| Q2 24 | $21.6M | $170.9M |
| Q1 26 | — | $162.4M | ||
| Q4 25 | $42.2M | $173.6M | ||
| Q3 25 | $31.6M | $174.8M | ||
| Q2 25 | $40.7M | $164.9M | ||
| Q1 25 | $22.3M | $168.0M | ||
| Q4 24 | $32.2M | $180.3M | ||
| Q3 24 | $44.8M | $194.4M | ||
| Q2 24 | $42.3M | $198.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-11.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -0.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-11.7M | ||
| Q4 25 | $-1.1M | $762.0K | ||
| Q3 25 | $-9.0M | $-979.0K | ||
| Q2 25 | $-3.4M | $-4.2M | ||
| Q1 25 | $-8.2M | $-10.5M | ||
| Q4 24 | $-36.3M | $2.1M | ||
| Q3 24 | $-7.5M | $-2.9M | ||
| Q2 24 | $-10.0M | $-650.0K |
| Q1 26 | — | — | ||
| Q4 25 | — | $255.0K | ||
| Q3 25 | — | $-2.0M | ||
| Q2 25 | $-3.4M | $-5.2M | ||
| Q1 25 | $-8.3M | $-11.0M | ||
| Q4 24 | $-36.4M | $1.5M | ||
| Q3 24 | $-7.5M | $-3.7M | ||
| Q2 24 | $-10.0M | $-1.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | -5.0% | ||
| Q2 25 | -116.5% | -13.6% | ||
| Q1 25 | -1976.7% | -30.1% | ||
| Q4 24 | -2309.3% | 4.1% | ||
| Q3 24 | -225.7% | -10.3% | ||
| Q2 24 | -376.2% | -3.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 1.2% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.9% | 2.5% | ||
| Q1 25 | 35.6% | 1.4% | ||
| Q4 24 | 4.2% | 1.5% | ||
| Q3 24 | 0.0% | 2.4% | ||
| Q2 24 | 0.4% | 1.8% |
| Q1 26 | — | — | ||
| Q4 25 | -0.68× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
LAW
Segment breakdown not available.
